Physician profile
Scott R Dalton
NPI 1497725576
$6,318.48
in general payments reported to CMS, 2019-2025
31 companies · $919 in 2025
The $919 reported for 2025 was more than what a typical Dermatopathology (Dermatology) provider received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,066 · 2020: $580 · 2021: $550 · 2022: $891 · 2023: $839 · 2024: $1,472 · 2025: $919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,222 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,222.34 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $945.03 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Abbvie INC. | $624.55 | 2019-2024 | Skyrizi, Rinvoq |
| E.R. Squibb & Sons, L.L.C. | $468.84 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $408.48 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $387.89 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $349.41 | 2020-2025 | Absorica Ld, Winlevi |
| Almirall LLC | $338.98 | 2019-2025 | Klisyri, Seysara |
| Incyte Corporation | $324.49 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $303.20 | 2019-2025 | Libtayo, Dupixent |
| Pfizer INC. | $267.81 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $251.21 | 2023-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $250.18 | 2019-2025 | |
| Ucb, INC. | $236.77 | 2020-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $202.25 | 2019-2022 | |
| Janssen Biotech, INC. | $192.63 | 2021-2025 | Tremfya |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $162.81 | 2023-2024 | Vtama |
| Journey Medical Corporation | $124.60 | 2019-2022 | |
| Revance Therapeutics, INC. | $90.26 | 2024 | Daxxify |
| Leo Pharma INC. | $82.37 | 2020-2024 | Adbry |
| Mylan Pharmaceuticals INC. | $66.70 | 2019 | |
| Amgen INC. | $47.92 | 2022 | |
| Novartis Pharmaceuticals Corporation | $24.89 | 2021-2023 | |
| Janssen Scientific Affairs, LLC | $24.60 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.39 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.61 | 2022 | |
| Celgene Corporation | $19.09 | 2019 | |
| Dermira, INC. | $18.98 | 2020 | |
| Mission Pharmacal Company | $18.05 | 2019 | |
| Botanix Sb INC | $17.58 | 2025 | Sofdra |
| Organon LLC | $16.02 | 2025 | |
| Promius Pharma LLC | $12.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Dalton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.